Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 12/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 11/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 11/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610213 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TDP1GNAO1GNAI3GNAI1 | |
| SCHEMBL14395367 | 0.92 | SMN1; SMN2 (0.48) | ALDH1A1TDP1GNAO1GNAI3GNAI1 | |
| SCHEMBL20017937 | 0.89 | ALDH1A1 (0.49) | ALDH1A1TDP1GNAO1GNAI3GNAI1 | |
| SCHEMBL13610209 | 0.89 | ALDH1A1 (0.49) | ALDH1A1TDP1GNAO1GNAI3GNAI1 | |
| SCHEMBL130841 | 0.86 | ALDH1A1 (0.61) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL8434237 | 0.86 | ALDH1A1 (0.61) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL13923572 | 0.86 | ALDH1A1 (0.61) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL125673 | 0.83 | ALDH1A1 (0.57) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL11995969 | 0.82 | ALDH1A1 (0.57) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL130814 | 0.82 | ALDH1A1 (0.57) | ALDH1A1TDP1SMN1; SMN2MEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455520-B2 | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20100197691-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| EP-2178534-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck Sharp & Dohme Corp. (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009011872-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197691-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | EPHX1, EPHX2, PTGIS | ALDH1A1 487/4885TDP1 1969/4885GNAO1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.